Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Japan Tissue Engineering Co's net current asset value per share for the quarter that ended in Mar. 2026 was 円88.39.
The historical rank and industry rank for Japan Tissue Engineering Co's Net Current Asset Value or its related term are showing as below:
TSE:7774'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.9 Med: 5.81 Max: 12.06
Current: 9.74
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Japan Tissue Engineering Co was 12.06. The lowest was 3.90. And the median was 5.81.
TSE:7774's Price-to-Net-Current-Asset-Value is ranked worse than 71.43% of 931
companies
in the Biotechnology industry
Industry Median: 4.8
vs TSE:7774: 9.74
Japan Tissue Engineering Co (TSE:7774) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Japan Tissue Engineering Co Net Current Asset Value Related Terms
Japan Tissue Engineering Co Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Japan Tissue Engineering Co Net Current Asset Value Chart
TSE:7774 vs VRTX, REGN, MRNA: Net Current Asset Value Comparison
For the Biotechnology subindustry, Japan Tissue Engineering Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Tissue Engineering Co Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Japan Tissue Engineering Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Japan Tissue Engineering Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of 円88.39 mean?
Japan Tissue Engineering Co (TSE:7774) has a Net Current Asset Value of 円88.39 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Japan Tissue Engineering Co and its competitors. According to the industry distribution chart, Japan Tissue Engineering Co ranks #665 out of 931 companies in the Biotechnology industry, placing it in the top 71.4%.
Is Japan Tissue Engineering Co's Net Current Asset Value too high?
Japan Tissue Engineering Co's current Net Current Asset Value is 円88.39. Based on the distribution chart, Japan Tissue Engineering Co ranks #665 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Japan Tissue Engineering Co has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Japan Tissue Engineering Co ranks #665 out of 931 companies for Net Current Asset Value. This places Japan Tissue Engineering Co in the lower half of its industry. The industry median Net Current Asset Value is 4.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.80, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Japan Tissue Engineering Co and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Japan Tissue Engineering Co's current Net Current Asset Value is 円88.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Significantly Overvalued. The stock's GF Value™ is 円505.49, compared to a current price of 円878.00 — trading 73.7% above its estimated fair value. The current Net Current Asset Value is 円88.39. Japan Tissue Engineering Co's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Net Current Asset Value is 円88.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued.
The current stock price of 円878.00 is trading 73.7% above its estimated GF Value™ of 円505.49.
GuruFocus considers Japan Tissue Engineering Co to be Significantly Overvalued.
Key valuation signals for TSE:7774:
Net Current Asset Value: 円88.39
GF Value™: 円505.49 vs. price of 円878.00 (73.7% above fair value)
No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
57GF Score
Get the complete analysis for TSE:7774
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7774 has been successfully added to your 
